

**Hot Science**

Friday, November 2, 2012 | 2:00 – 4:00 p.m. | Room 20 A/B

Moderators:

*Terry J. Watnick, MD and Matthew R. Weir, MD*

- 2:00 p.m.**      **The Pathological Role of FGF23 in the Cardiorenal Syndrome Is Mediated by the Activation of Calcineurin/NFAT Signaling in the Heart** — *Ansel P. Amaral, Alexis J. Sloan, Saurav Singh, Ming Chang Hu, Orson W. Moe, Makoto Kuroo, Giovana S. Di Marco, Marcus Brand, Myles S. Wolf, Christian Faul.* Miami, FL.
- 2:12 p.m.**      **Molecular Mechanisms of Cadmium (Cd) Dependent Fibroblast Growth Factor 23 Secretion in Bone** — *Shinsuke Kido, Marina Fujihara, Kengo Nomura, Shohei Sasaki, Yuji Shiozaki, Hiroko Segawa, Sawako Tatsumi, Ken-ichi Miyamoto.* Tokushima, Japan.
- 2:24 p.m.**      **T-Cell Autophagy Is Required for Transplantation Tolerance** — *Divya Anna Verghese, Peyman Bizargity, Anju Yadav, Barbara T. Murphy, Bernd Schroppel.* New York, NY
- 2:36 p.m.**      **Absence of Adenylyl Cyclase 6 Is Markedly Protective in Polycystic Kidney Disease in Mice** — *Donald E. Kohan, Karl P. Roos, Kevin A. Strait, Sara Rees.* Salt Lake City, UT.
- 2:48 p.m.**      **Wnt Signaling Is Required for Kidney Regeneration from Adult Zebrafish Nephron Progenitor Cells** — *Caramai Nanae Kameji, Yan Liu, Iain A. Drummond.* Charlestown, MA.
- 3:00 p.m.**      **Missense Mutation in Cell Cycle Gene FSGS7 Is a Cause of Autosomal Dominant FSGS** — *Rasheed A. Gbadegesin, Gentzon Hall, Guanghong Wu, David Howell, Mario Schiffer, Michelle P. Winn.* Durham, NC.
- 3:12 p.m.**      **Endophilin, a Functional Partner of Dynamin and Synaptojanin 1 at Synapses, Is Required for Podocyte Function in the Kidney** — *Keita Soda, Xuefei Tian, Sung Hyun Son, Shuta Ishibe.* New Haven, CT.
- 3:24 p.m.**      **Feasibility of Repairing GBM Defects in Alport Syndrome** — *Jeffrey H. Miner, Xiaobo Lin.* St. Louis, MO.
- 3:36 p.m.**      **Disruption of PHD2 in the Kidney Results in HIF-2 Dependent Polycythemia** — *Pinelopi P. Kapitsinou, Volker H. Haase.* Nashville, TN.
- 3:36 p.m.**      **Insights into ANCA-associated Vasculitis Provided by the First Genome-wide Association Study** — *Kenneth G.C. Smith.* Cambridge, United Kingdom.

**High-Impact Clinical Trials**

Saturday, November 3, 2012 | 10:30 a.m. – 12:30 p.m. | Hall D

*Moderators:**Julie R. Ingelfinger, MD and David R.W. Jayne, MD*

- 10:30 a.m. Introduction**
- 10:36 a.m. The Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) —** *Hans-Henrik Parving, Barry M. Brenner, John McMurray, Dick de Zeeuw, Steven Mark Haffner, Scott D. Solomon, Nish Chaturvedi, Frederik I. Persson, Akshay Suvas Desai, Maria Nicolaidis, Marc A. Pfeffer.* Copenhagen, Denmark.
- 10:54 a.m. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Trial —** *Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John Ouyang, Osamu Sato, Frank S. Czerwiec.* Rochester, MN.
- 11:12 a.m. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) Trial —** *Glenn M. Chertow, Geoffrey A. Block, Ricardo Correa-Rotter, Tilman B. Drueke, Jürgen Floege, William G. Goodman, Christian Mix, Marie-Louise Trotman, Yumi Kubo, Charles A. Herzog, Gerard M. London, Kenneth Mahaffey, Sharon M. Moe, David C. Wheeler, Patrick S. Parfrey.* Stanford, CA.
- 11:30 a.m. A Randomised Trial of Mycophenolate Mofetil versus Cyclophosphamide for Remission Induction in ANCA-Associated Vasculitis: MYCYC —** *Rachel B. Jones, Michael Walsh, On behalf of the European Vasculitis Study Group.* Cambridge, United Kingdom.
- 11:48 a.m. Survival of Dialysis Patients in the US after Surgical Versus Percutaneous Coronary Intervention —** *Charles A. Herzog, Craig Solid.* Minneapolis, MN.
- 12:06 p.m. Ten-Year Safety of Prediabetic Living Kidney Donors —** *Sindhu Chandran, Umesh Masharani, Allison B. Webber, David Wojciechowski.* San Francisco, CA.
- 12:24 p.m. Wrap-Up**